ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.1 HKD | -1.12% |
|
-4.08% | -52.84% |
06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
05-30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
![Consensus](/images/consensus_flch.gif)
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-52.84% | 679M | |
+14.84% | 121B | |
+18.31% | 112B | |
+2.94% | 22.72B | |
-18.26% | 20.82B | |
-18.47% | 16.66B | |
-42.36% | 16.36B | |
-14.23% | 16.19B | |
-0.68% | 13.17B | |
+21.87% | 11.11B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug